Cargando…
Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats
BACKGROUND: Opioid use disorders are serious contributors to the harms associated with the drug use. Unfortunately, therapeutic interventions for opioid addicts after detoxification have been limited and not sufficiently effective. Recently, several studies have led to promising results with disulfi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599263/ https://www.ncbi.nlm.nih.gov/pubmed/34236605 http://dx.doi.org/10.1007/s43440-021-00307-2 |
_version_ | 1784600910907834368 |
---|---|
author | Frankowska, Małgorzata Surówka, Paulina Suder, Agata Pieniążek, Renata Pukło, Renata Jastrzębska, Joanna Daniel, Władysława A. Filip, Małgorzata Zadrożny-Bujalska, Magdalena Kleczkowska, Patrycja |
author_facet | Frankowska, Małgorzata Surówka, Paulina Suder, Agata Pieniążek, Renata Pukło, Renata Jastrzębska, Joanna Daniel, Władysława A. Filip, Małgorzata Zadrożny-Bujalska, Magdalena Kleczkowska, Patrycja |
author_sort | Frankowska, Małgorzata |
collection | PubMed |
description | BACKGROUND: Opioid use disorders are serious contributors to the harms associated with the drug use. Unfortunately, therapeutic interventions for opioid addicts after detoxification have been limited and not sufficiently effective. Recently, several studies have led to promising results with disulfiram (DSF), a dopamine β-hydroxylase (DBH) inhibitor, showing that it is a potent agent against not only alcohol but also addiction to various drugs. MATERIALS AND METHODS: This study was designed to examine whether DSF and nepicastat (NEP; another DBH inhibitor) modify morphine intake and reinstatement of seeking-behavior using the rat model of intravenous morphine self-administration. Additionally, we intended to estimate the effects of both inhibitors on the locomotor activity as well as on extracellular dopamine and its metabolite levels in the nucleus accumbens using microdialysis in naive rats. RESULTS: We demonstrated that both DBH inhibitors reduced responding to morphine self-administration. Moreover, DSF and NEP administered acutely before reinstatement test sessions consistently attenuated the reinforcing effects of morphine and a morphine-associated conditioned cue. The observed effects for lower doses (6.25–25 mg/kg; ip) of both DBH inhibitors seem to be independent of locomotor activity reduction and dopamine level in the nucleus accumbens. Neither DSF nor NEP administered daily during morphine abstinence with extinction training sessions had any effect on active lever-responding and changed the reinstatement induced by morphine priming doses. Reinstatement of drug-seeking behavior induced by a conditioned cue previously associated with morphine delivery was attenuated following repeated administration of DSF or NEP during the abstinence period. CONCLUSION: These results seem to point to the significance of DBH inhibition as a potential pharmacotherapy against morphine use disorders. GRAPHIC ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-8599263 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-85992632021-11-24 Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats Frankowska, Małgorzata Surówka, Paulina Suder, Agata Pieniążek, Renata Pukło, Renata Jastrzębska, Joanna Daniel, Władysława A. Filip, Małgorzata Zadrożny-Bujalska, Magdalena Kleczkowska, Patrycja Pharmacol Rep Article BACKGROUND: Opioid use disorders are serious contributors to the harms associated with the drug use. Unfortunately, therapeutic interventions for opioid addicts after detoxification have been limited and not sufficiently effective. Recently, several studies have led to promising results with disulfiram (DSF), a dopamine β-hydroxylase (DBH) inhibitor, showing that it is a potent agent against not only alcohol but also addiction to various drugs. MATERIALS AND METHODS: This study was designed to examine whether DSF and nepicastat (NEP; another DBH inhibitor) modify morphine intake and reinstatement of seeking-behavior using the rat model of intravenous morphine self-administration. Additionally, we intended to estimate the effects of both inhibitors on the locomotor activity as well as on extracellular dopamine and its metabolite levels in the nucleus accumbens using microdialysis in naive rats. RESULTS: We demonstrated that both DBH inhibitors reduced responding to morphine self-administration. Moreover, DSF and NEP administered acutely before reinstatement test sessions consistently attenuated the reinforcing effects of morphine and a morphine-associated conditioned cue. The observed effects for lower doses (6.25–25 mg/kg; ip) of both DBH inhibitors seem to be independent of locomotor activity reduction and dopamine level in the nucleus accumbens. Neither DSF nor NEP administered daily during morphine abstinence with extinction training sessions had any effect on active lever-responding and changed the reinstatement induced by morphine priming doses. Reinstatement of drug-seeking behavior induced by a conditioned cue previously associated with morphine delivery was attenuated following repeated administration of DSF or NEP during the abstinence period. CONCLUSION: These results seem to point to the significance of DBH inhibition as a potential pharmacotherapy against morphine use disorders. GRAPHIC ABSTRACT: [Image: see text] Springer International Publishing 2021-07-08 2021 /pmc/articles/PMC8599263/ /pubmed/34236605 http://dx.doi.org/10.1007/s43440-021-00307-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Frankowska, Małgorzata Surówka, Paulina Suder, Agata Pieniążek, Renata Pukło, Renata Jastrzębska, Joanna Daniel, Władysława A. Filip, Małgorzata Zadrożny-Bujalska, Magdalena Kleczkowska, Patrycja Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats |
title | Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats |
title_full | Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats |
title_fullStr | Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats |
title_full_unstemmed | Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats |
title_short | Treatment with dopamine β-hydroxylase (DBH) inhibitors prevents morphine use and relapse-like behavior in rats |
title_sort | treatment with dopamine β-hydroxylase (dbh) inhibitors prevents morphine use and relapse-like behavior in rats |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8599263/ https://www.ncbi.nlm.nih.gov/pubmed/34236605 http://dx.doi.org/10.1007/s43440-021-00307-2 |
work_keys_str_mv | AT frankowskamałgorzata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT surowkapaulina treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT suderagata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT pieniazekrenata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT pukłorenata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT jastrzebskajoanna treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT danielwładysławaa treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT filipmałgorzata treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT zadroznybujalskamagdalena treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats AT kleczkowskapatrycja treatmentwithdopaminebhydroxylasedbhinhibitorspreventsmorphineuseandrelapselikebehaviorinrats |